Pfizer earnings beat estimates as drugmaker raises 2026 outlook
Pfizer (PFE) reported Q3 earnings of $0.87 per share, beating estimates of $0.73, with revenue at $16.6B, also topping forecasts. Net income fell 8% to $3.24B. The company raised its 2023 adjusted earnings guidance to $2.95-$3.05 per share and revenue forecast to $62B-$64B, citing strong performance.
How this was made
The 30-second read
Why it matters
The key tradable change is the raised 2026 profit and revenue outlook following a Q3 adjusted EPS and revenue beat, which can shift consensus estimates and forward multiples.
Market read
Guidance uplift after an earnings beat is a direct catalyst for repricing Pfizer’s 2026 earnings power.
What to watch
Comirnaty and Paxlovid exclusions are central; traders may scrutinize whether the 32% growth from launched and acquired products can offset ongoing declines in other lines.
Background
Pfizer’s results are framed around growth outside COVID-19 products, with Comirnaty and Paxlovid called out separately.
Ticker impact
Pfizer beat Q3 adjusted EPS ($0.87 vs $0.73) and raised 2026 adjusted earnings to $2.95-$3.05 and revenue to $62B-$64B.
Likely upward pressure as the market reprices 2026 earnings and revenue expectations following the guidance raise.
The article reports both a quarterly beat and explicit, higher full-year EPS and revenue ranges, which are direct drivers of valuation and positioning.
Market effects
Positive read-through for large-cap pharma earnings durability, especially around non-COVID growth offsetting declines elsewhere.
US-listed pharma sentiment may improve modestly, with potential spillover to European pharma peers via guidance sentiment.
Limited direct global macro linkage, but guidance revisions can influence cross-market pharma risk appetite.
Counterpoint
The article notes revenue was roughly flat year over year, so the market may focus on sustainability of growth outside COVID products rather than the headline beat.
Key entities
- companyPfizer Inc
Dosed and commercialized therapies; reported Q3 beat and raised 2026 adjusted earnings and revenue forecasts.
